Overseas income sharply decreased, impacting performance, and the funding projects of Otaibio have been delayed.

① Due to the impact of international situations, economic policies, and fluctuations in the overall market, the fundraising projects of Aotai Biological aimed at expanding overseas markets will be delayed. ② Overseas revenue has always been the most core source of income for Aotai Biological, with the overall income proportion once reaching 99.83%, and the sharp decline in overseas revenue has also led to a significant drop in Aotai Biological's overall income.

cls.cnDec 26, 2024 16:37

Henan Lingrui Pharmaceutical plans to acquire Silver Valley Pharmaceutical for 0.782 billion, entering the market of traditional Chinese medicine plaster agents as a leading player in crossover pharmaceutical markets. | Quick summary announcement.

① Henan Lingrui Pharmaceutical plans to acquire all equity of Yingu Pharmaceutical for 0.782 billion yuan, entering the chemical and innovative drugs market. ② According to data from MoShang Pharmaceuticals, Yingu Pharmaceutical's sales exceeded 0.4 billion yuan in 2023, with the top-selling product being Jin'erli, accounting for about 70% of the company's total revenue, and the growth rate of the Class 1 new drug Bilitin is relatively fast. ③ If the acquisition of Yingu Pharmaceutical proceeds smoothly, the difficulty of achieving the previously set stock-based incentive unlock goals may be significantly reduced.

cls.cnDec 4, 2024 23:07

Henan Lingrui Pharmaceutical disclosed a stock-based incentive plan. Unlocking conditions: annual average double-digit growth in non-net income. | Speed read announcement

Henan Lingrui Pharmaceutical has announced a new round of restricted stock incentive plan and employee stock ownership plan, with slightly lowered performance assessment targets compared to the previous incentive plan, but still maintaining double-digit non-GAAP performance assessment requirements. In addition to Henan Lingrui Pharmaceutical, Tibet Cheezheng Tibetan Medicine has also announced an employee stock ownership plan with high performance targets, and the industry expects bone health to be a high-potential product category in the outpatient market.

cls.cnNov 29, 2024 23:25

Insurance capital is intensively increasing stakes in dividend stocks! What is the reason?

Currently, there are quite a few shareholders of insurance funds that hold more than 5% of the circulating shares of listed companies. In addition to some being unlocked restricted shares, there have also been many actions of shareholding and new stakes taken, with at least 14 instances of such actions this year.

China brokerageNov 20, 2024 09:58

Abnormal trading investigation! The big bull stock special treat Jingfeng has been suspended for the first time, with an increase of over 752% in more than four months | Quick read of the announcement.

①*ST Jingfeng suspended trading for the first time this year due to abnormal fluctuations; ② The cumulative deviation of the closing price for two consecutive trading days reached 15.39%; ③ The stock price has increased by 752.78% in the past four months; ④ There is still uncertainty about the highly anticipated pre-restructuring matters.

cls.cnNov 17, 2024 19:31

Stocks are hitting the ceiling! Since October, 10 A-share listed companies have announced being targeted, with china national medicines corporation and sh pharma being targeted on the same day by new china life insurance.

① According to incomplete statistics, since October, 10 A-share listed companies including zhejiang east crystal electronic, semiconductor manufacturing international corporation, quanjinhao, lifecome biochemistry, zhejiang jingu, primeton information technologies, inc., guangzhou goaland energy conservation tech, xuzhou handler special vehicle, china national medicines corporation, and sh pharma have announced that they have received major stock purchases from relevant parties (see attached table). ② In the secondary market, this week, xuzhou handler special vehicle and guangzhou goaland energy conservation tech have both seen their stock prices increase by more than 100% since September.

cls.cnNov 17, 2024 15:30